NCT07654803

Brief Summary

This study aims to evaluate the clinical feasibility of a millimeter-wave radar sleep monitoring system in the diagnosis of Narcolepsy Type 1 (NT1). Narcolepsy is a chronic central nervous system sleep disorder characterized by excessive daytime sleepiness as its core symptom. NT1 is defined by the presence of cataplexy or reduced cerebrospinal fluid hypocretin-1 (Hcrt-1) levels. The current diagnostic gold standard relies on overnight polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT); however, conventional methods are limited by complex operation, time-consuming procedures, high patient compliance demands, and poor scalability in primary care settings. This prospective, single-center, concurrent validation study plans to enroll 40 clinically diagnosed NT1 patients. Participants will undergo simultaneous PSG/MSLT and millimeter-wave radar sleep monitoring. Using PSG/MSLT as the gold standard, we will assess the consistency and accuracy of the radar system in identifying core parameters, including mean sleep latency (MSL), sleep-onset rapid eye movement period (SOREMP) count, and sleep architecture, while also evaluating data integrity and patient compliance. Key collected indicators include: demographic characteristics, clinical symptoms, Hcrt-1 levels, HLA genotyping, PSG parameters (total sleep time \[TST\], sleep efficiency \[SE\], sleep latency \[SL\], REM latency, SOREMP, sleep stage proportions, apnea-hypopnea index \[AHI\], periodic limb movement index \[PLMI\]), MSLT parameters (MSL, SOREMP count), and radar system parameters (TST, SL, SE, arousal frequency, etc.). Statistical analysis will be performed using SPSS 23.0. Normally distributed continuous variables will be analyzed using independent samples t-tests, non-normally distributed data using Mann-Whitney U tests, and categorical variables using chi-square tests. The study duration is 7 months (May to December 2026). This research may provide a non-contact, convenient, and cost-effective alternative or supplementary monitoring approach for narcolepsy, promoting the application of outpatient and home-based sleep monitoring.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for all trials

Timeline
19mo left

Started May 2026

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress7%
May 2026Dec 2027

Study Start

First participant enrolled

May 7, 2026

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

June 12, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 17, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

June 17, 2026

Status Verified

June 1, 2026

Enrollment Period

8 months

First QC Date

June 12, 2026

Last Update Submit

June 12, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Whether type 1 narcolepsy is present

    The entire process, from enrollment to completion of assessments, takes one day.

Study Arms (1)

narcolepsy group and control group

Eligibility Criteria

Sexall(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with sleep disorders

You may qualify if:

  • (1) Patients clinically diagnosed with type 1 narcolepsy; (2) Agree to undergo overnight polysomnography (PSG) and the subsequent daytime multiple sleep latency test (MSLT), with monitoring duration meeting the PSG/MSLT scoring requirements (PSG recording duration ≥ 7 hours, total MSLT procedure duration ≥ 10 hours); (3) Simultaneous data collection using a millimeter-wave radar sleep monitoring system during the monitoring period, with complete and uninterrupted signal acquisition; (4) Complete clinical data available; (5) Willing to participate in this study and sign the informed consent form (if the participant is under 18 years of age, both the participant's assent and the written informed consent of the legal guardian are required).

You may not qualify if:

  • (1) Refusal to sign the informed consent form; (2) Inability to complete the full protocol of overnight PSG and the subsequent daytime MSLT due to irregular sleep-wake schedules (e.g., shift work, travel across time zones) or poor compliance; (3) Loss of raw data or poor signal quality during millimeter-wave radar signal acquisition caused by substantial body movements, getting out of bed, environmental interference, or other factors, making effective analysis impossible.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First Affiliated Hospital of PLA Air Force Medical University

Xi'an, Shaanxi, China

Location

Related Publications (2)

  • Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep. 1986 Dec;9(4):519-24. doi: 10.1093/sleep/9.4.519. No abstract available.

  • [1] American Academy of Sleep Medicine. International classification of sleep disorders-third edition (ICSD-3)[M]. Darien IL: American Academy of Sleep Medicine, 2014

    RESULT

MeSH Terms

Conditions

Disorders of Excessive Somnolence

Condition Hierarchy (Ancestors)

Sleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental Disorders

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2026

First Posted

June 17, 2026

Study Start

May 7, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Last Updated

June 17, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Involves participant privacy and personally sensitive information, and is subject to data protection regulations.

Locations